Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae

H. Ikejima, H. Yamamoto, K. Ishida, S. Terakubo, M. Kaku, J. Shimada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

We examined the in-vitro activities of various antibiotics against 25 strains of Mycoplasma pneumoniae (22 clinical isolates and 3 standard strains). In the 22 clinical isolates, the 90% minimum inhibitory concentrations (MIC 90) of SCH27899, ofloxacin, levofloxacin, ciprofloxacin, erythromycin, clarithromycin, roxithromycin, clindamycin, and minocycline were 16, 2, 2, 4, 0.0039, 0.0039, 0.016, 2, and 4 μg/ml, respectively. The minimum bactericidal concentrations (MBC 90) of SCH27899, ofloxacin, levofloxacin, ciprofloxacin, erythromycin, clarithromycin, roxithromycin, clindamycin, and minocycline were 64, 4, 2, 8, 0.0625, 0.0625, 0.125, 8, and 64 μg/ml, respectively. The low sensitivity of M. pneumoniae to SCH27899 may be a result of the impermeability of the bacteria to this molecule. The results of this study suggest that SCH27899 would not be a suitable antimicrobial agent to use in the alternative chemotherapy of M. pneumoniae infection.

Original languageEnglish
Pages (from-to)121-123
Number of pages3
JournalJournal of Infection and Chemotherapy
Volume7
Issue number2
DOIs
Publication statusPublished - 2001 Jan 1

Keywords

  • Everninomicin
  • Mycoplasma pneumoniae
  • SCH27899

ASJC Scopus subject areas

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Comparison of in-vitro activities of SCH27899 and other antibiotics against Mycoplasma pneumoniae'. Together they form a unique fingerprint.

  • Cite this